Axogen Shorts Build Ahead of Wednesday Results

Axogen reports quarterly results on October 29, and the stock arrives at that moment with short interest at an 11% level, a clutch of new analyst coverage, and a notable attention spike that stands out from a normally quiet name.

Short interest has climbed sharply over the past month. At roughly 11% of the free float, the position is meaningfully elevated and has grown around 32% over the past 30 days, with most of that build occurring in the final two weeks of October. The recent addition of approximately 270,000 shares to the short book in the past week alone suggests active repositioning ahead of the print, not passive drift. That said, the borrow market is not under any stress. Availability is running at 833%, meaning there are more than eight shares available to lend for every one already borrowed. Cost to borrow is just 0.47%, which has actually eased slightly over the week. Bears can add to positions cheaply and easily. The options market is similarly relaxed, with a put/call ratio of 0.05, barely above its 20-day average and nowhere near the levels that would signal defensive panic.

The analyst community has become notably more active on the stock over the past month. Barclays and B of A Securities both initiated coverage in early October with Overweight and Buy ratings respectively, Barclays at a $55 target and BofA at $52. Barclays then trimmed its target to $50 on October 23 ahead of results, the first sign of pre-earnings caution from a firm that had been bullish for less than three weeks. Truist and Raymond James both carry Buy-equivalent ratings, with targets between $53 and $60. The mean analyst target is $53.09 against a current price of $37.46, implying roughly 42% upside, one of the larger gaps between price and consensus that the Street has attached to this name. EPS momentum over the past 30 and 90 days ranks in the 92nd and 76th percentiles respectively, though the EPS surprise score is low at just the 8th percentile, a reminder that beating estimates has not been a consistent pattern. The analyst recommendations differential scores at the 100th percentile, meaning the tilt of ratings relative to the sector is about as bullish as it gets.

The bull case rests on Avance's BLA biological classification, secured in 2025, which carries 12-year reference exclusivity through 2037. That regulatory moat matters in a peripheral nerve repair market the company estimates at around $5 billion, where penetration is still low and surgeon uptake has been broadening. The bear case is less about competition than execution: gross margin pressure from the shift to a biologic quality system, payer resistance on newer indications such as cavernous nerve grafting, and the cost of expanding the sales force could constrain operating leverage even as revenue grows. The EV/EBITDA multiple of around 41 times, down about 5 turns over the past 30 days, reflects a market that has already started discounting some of that uncertainty.

One institutional development worth noting: Divisadero Street Capital Management filed a Schedule 13G on October 2, disclosing a 6.8% stake of roughly 3.98 million shares. That is a new 13G filing from a first-time filer, meaning this is a fresh position rather than a continuation. Separately, individual investor Mathew P. Arens has raised a disclosed stake to 7.58%, up from 6.8% earlier in the year. No 13D activists are on the register, and all 13D/G positions are disclosed around the 5% threshold, holders dropping below that level may not file again.

Insider activity over the past 90 days has been one-sided on net, with the reported net sale value running at roughly $4.7 million in aggregate. Every transaction in the recent record is tagged as operating under a pre-arranged 10b5-1 plan, which reduces the informational content of any individual sale. The August transactions were a mix of option exercises and same-day sales at prices in the high $40s, well above the current $37.46 level, a reminder that the stock has given back around 14% over the past month.

The results on October 29 will clarify whether the short build reflects genuine concern about the quarter or simply event-driven hedging that unwinds quickly. The last reported quarterly result in August lifted the stock 8.7% on the day and 9.9% over the subsequent five days, so a positive surprise has a clear historical price response to benchmark against.